NEW YORK (GenomeWeb News) - Ciphergen Biosystems announced today that it is established a scientific advisory board to "assist in directing the company's product development strategies."
There are five members in the advisory board:
Robert Bast, vice president for translational research and a professor at the University of Texas MD Anderson Center is best known for developing the Ovarian Cancer 125 monoclonal antibody that led to the production of the CA125 radioimmunoassay for the monitoring of epithelial ovarian cancer.
Danel Chan, a professor of pathology, oncology, urology, and radiology, and the director of the Center for Biomarker Discovery at the Johns Hopkins University School of Medicine is recognized for his work in finding and developing biochemical tumor markers, particularly for breast and prostate cancer.
Ian Jacobs, director of the Department of Gynecological Oncology and the Institute of Women's Health at University College London has conducted laboratory studies on the genetic basis of gynecological cancer, and headed the UK Collaborative Trial of Ovarian Cancer Screening involving 200,000 women in the UK.
Joyce Schwartz, vice president and chief laboratory officer of Quest Diagnostics is responsible for medical operations and medical quality for Quest's core laboratory testing business.
William Wallen is the senior vice president and chief scientific officer of Idexx Laboratories, a company that produces products and services for veterinary, food and water applications. Before joining Idexx, Wallen was senior vice president and head of the office of technology for the diagnostics division of Bayer Healthcare.